Pliant Therapeutics, Inc.

35 articles with Pliant Therapeutics, Inc.

• Pliant Therapeutics Presents Data at American Thoracic Society 2020 Virtual Sessions

  9/24/2020

   Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its data presentation at the American Thoracic Society (ATS) 2020 Virtual Sessions.  Pliant is evaluating PLN-74809 in fibr

• Pliant Therapeutics To Participate In Upcoming Virtual Investor Conferences

  9/4/2020

   Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that management will be participating in the following investor conferences in September 2020 :

• Pliant Therapeutics Presents Data at The Digital International Liver Congress™ 2020

  8/27/2020

  Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced that the company will be presenting data at The Digital International Liver Congress™ 2020.

• Pliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results

  8/11/2020

  Raised over $175 million in initial public offering and concurrent private placement to advance lead product candidate PLN-74809 for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis

• Pliant Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

  6/5/2020

   Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the closing of its initial public offering of 10,350,000 shares of common stock, which includes the exercise in full by the underwriters o

• Pliant Therapeutics Announces Pricing of Initial Public Offering

  6/3/2020

  Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a public offering price of $16.00 per share.

• Pliant Therapeutics Initiates First-in-Human Clinical Trial of PLN-1474 for the Potential Treatment of Liver Fibrosis

  3/23/2020

  Pliant Therapeutics, Inc., , today announced that it has dosed the first cohort of healthy participants in a first-in-human Phase 1 clinical trial of PLN-1474, a small molecule s

• Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases

  3/3/2020

  Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, announced that it has raised $100 million in a Series C financing.

• Pliant Therapeutics Appoints Gayle Crowell to its Board of Directors

  1/8/2020

  Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Gayle Crowell to its board of directors as an independent director.

• Pliant Therapeutics to Present Preclinical Data in Primary Sclerosing Cholangitis at The Liver Meeting 2019

  10/31/2019

  Pliant Therapeutics, Inc. announced that company scientists and research collaborators will present data highlighting Pliant's lead product candidate PLN-74809 at The Liver Meeting® 2019 hosted by the American Association for the Study of Liver Diseases (AASLD).

• Pliant Therapeutics Announces Strategic Collaboration to Develop Novel Therapies for NASH and Fibrotic Diseases

  10/23/2019

  Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced it has entered into a strategic collaboration and license agreement with Novartis covering the development and commercialization of Pliant's preclinical product candidate, PLN-1474 and up to three additional integrin targets.

• 

  Pliant Inks $80 Million+ Deal with Novartis on Liver Disease NASH

  10/23/2019

  The agreement revolves around the development and commercialization of Pliant’s preclinical candidate, PLN-1474, and up to three more integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis.

• Pliant Therapeutics Announces Publication Demonstrating Feasibility of Positron Emission Tomography (PET) Tracers for Imaging Fibrosis in Patients with Idiopathic Pulmonary Fibrosis

  10/15/2019

  Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of fibrosis, announced the publication of a study evaluating the use of a positron emission tomography (PET) tracer for the detection of idiopathic pulmonary fibrosis (IPF) through the recognition of protein integrin avb6.

• Pliant Therapeutics Reports Positive Results of Phase 1b Clinical Study Supporting Advancement of PLN-74809 for Treatment of Idiopathic Pulmonary Fibrosis

  6/27/2019

  Pliant Therapeutics, Inc. announced the successful completion of a Phase 1b clinical trial of its lead product candidate, PLN-74809, an oral small-molecule dual selective inhibitor of αvß6 and αvß1 integrins that is being developed for the treatment of idiopathic pulmonary fibrosis, and primary sclerosing cholangitis.

• Pliant Therapeutics Reports Positive Results of Phase 1 Clinical Study Support Advancement of PLN-74809 for Idiopathic Pulmonary Fibrosis

  4/9/2019

  Preclinical Studies Demonstrating Anti-fibrotic Effect of Integrin Inhibitor to be Presented at American Thoracic Society International Conference

• Pliant Therapeutics Presents Data in Human NASH Liver Tissue at The International Liver Congress 2019 Hosted by the European Association for the Study of the Liver (EASL)

  3/28/2019

  Pliant Therapeutics, Inc. announced the presentation of in vivo data highlighting product candidate PLN-1474 for fibrotic liver diseases in an oral presentation at The International Liver Congress™ 2019 hosted by the European Association for the Study of the Liver.

• Pliant Therapeutics Appoints Smital Shah to its Board of Directors

  3/14/2019

   Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced the appointment of Smital Shah to its board of directors as an independent director.

• Pliant Therapeutics to Present at Upcoming Investor Conferences

  2/13/2019

  Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., president and chief executive officer, will present an update on the company and its programs at two upcoming healthcare investor conferences.

• 

  BioSpace Movers and Shakers: Jan. 4

  1/4/2019

  Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.

• Pliant Therapeutics Appoints Keith Cummings as Chief Financial Officer and Eduard Gorina as Vice President, Clinical Development

  1/3/2019

  Pliant Therapeutics, Inc., a biotechnology company unraveling and targeting the key biological pathways driving fibrosis, today announced that Keith Cummings, M.D., MBA, has joined the company as chief financial officer and Eduard Gorina, M.D., has joined as vice president, clinical development.